105 Participants Needed

Palliative Care for Leukemia

EL
EH
Mv
KM
Overseen ByKatherine Murphy
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Virginia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the treatment Palliative Care, Supportive Care, End-of-Life Care, Symptom Management for leukemia?

Research shows that early integration of palliative care with standard treatment for leukemia can help manage painful symptoms and improve the quality of life for patients. It also highlights the benefits of palliative care in reducing unnecessary suffering and providing better support for both patients and caregivers.12345

Is palliative care safe for leukemia patients?

Palliative care, which focuses on improving quality of life and managing symptoms, is generally considered safe for leukemia patients. It has been shown to improve quality of life and psychological outcomes when integrated early with standard leukemia care.45678

How is palliative care different from other treatments for leukemia?

Palliative care for leukemia focuses on relieving symptoms and improving quality of life rather than curing the disease. It is unique because it addresses not only physical symptoms but also emotional, social, and spiritual needs, providing support to both patients and their families throughout the illness.235910

Research Team

KB

Karen Ballen, MD

Principal Investigator

University of Virginia

Eligibility Criteria

This trial is for adults aged 18 and older with a new or relapsed diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML). Participants must be able to consent, follow the study plan, and not have Acute Promyelocytic Leukemia.

Inclusion Criteria

I am 65 or older with a new diagnosis of AML, ALL, high-risk MDS, or high-risk CMML.
I am 18 or older with a specific type of blood cancer that has not responded to treatment.
My leukemia has not responded to at least two rounds of chemotherapy.
See 5 more

Exclusion Criteria

I do not have Acute Promyelocytic Leukemia.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants in the intervention group will have regular visits with a palliative care specialist, twice a week in the hospital and about every other week out of the hospital. Monthly questionnaires will be completed.

2 years
Twice a week (in-hospital), every other week (out-of-hospital)

Standard Care

Participants in the standard care group will see a palliative care specialist only if referred by their oncologist. Monthly questionnaires will be completed.

2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment, including emergency department visits, hospice services use, and quality of life measures.

2 years

Treatment Details

Interventions

  • Palliative Care
Trial OverviewThe trial studies the impact of early and ongoing palliative care consultations on end-of-life issues for patients with certain high-risk leukemias or MDS. It aims to understand how this supportive care can benefit these individuals.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Palliative Care InterventionExperimental Treatment1 Intervention
Participants on this arm will see a palliative care specialist twice a week while they are in the hospital and about every other week when they are out of the hospital. If participants see their oncologist less often than every other week while they're out of the hospital, then visits with the palliative care specialist would be timed to occur on the same day as the oncologist visit. Participants will complete a questionnaire about once a month.
Group II: Standard Clinical CareActive Control1 Intervention
Participants will see a palliative care specialist only if they have a referral from their oncologist according to standard clinical care. Participants on this arm will not be discouraged from requesting a consult.

Palliative Care is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Palliative Care for:
  • Symptom management for various conditions including cancer, neurological disorders, and end-of-life care
🇺🇸
Approved in United States as Palliative Care for:
  • Symptom management for various conditions including cancer, neurological disorders, and end-of-life care
🇨🇦
Approved in Canada as Palliative Care for:
  • Symptom management for various conditions including cancer, neurological disorders, and end-of-life care

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Virginia

Lead Sponsor

Trials
802
Recruited
1,342,000+

Findings from Research

Palliative care has been shown to provide significant benefits for patients with hematologic malignancies and their caregivers, yet there is a notable gap in its integration into standard cancer care.
There is a pressing need for innovative models to integrate palliative care early in the treatment process for patients with hematologic malignancies, addressing their unique needs based on disease subtype.
Palliative care for patients with hematologic malignancies: are we meeting patients' needs early enough?Kayastha, N., LeBlanc, TW.[2022]
Integrating hematologists with palliative care specialists and pain therapists early in the treatment of acute leukemia can significantly improve patient management and reduce painful symptoms.
This collaborative approach aims to minimize unnecessary suffering and enhance the overall outcomes for patients undergoing intensive or novel treatments, addressing their complex clinical needs.
Pain and related complaints in patients with acute leukemia: time for simultaneous care in hemato-oncology.Niscola, P., Tendas, A., Mazzone, C., et al.[2019]
Palliative care is increasingly recognized as essential throughout the course of illness, yet patients with haematological malignancies often receive it later than those with other cancers, highlighting a need for earlier integration.
Effective communication and tailored strategies are crucial for providing palliative care to patients with haematological malignancies, considering their unique treatment needs and the complexities of their conditions.
Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care.Wedding, U.[2022]

References

Palliative care for patients with hematologic malignancies: are we meeting patients' needs early enough? [2022]
Pain and related complaints in patients with acute leukemia: time for simultaneous care in hemato-oncology. [2019]
Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care. [2022]
Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. [2021]
Nurses' perception of adequacy of care for leukemia patients with distress during the incurable phase and related factors. [2018]
Acute Leukemia Patients' Needs: Qualitative Findings and Opportunities for Early Palliative Care. [2019]
Top Ten Tips Palliative Care Clinicians Should Know About Acute Myeloid Leukemia. [2023]
Evaluating palliative opportunities in pediatric patients with leukemia and lymphoma. [2021]
Palliative care and hematologic oncology: the promise of collaboration. [2012]
10.United Statespubmed.ncbi.nlm.nih.gov
Specific challenges in end-of-life care for patients with hematological malignancies. [2020]